Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Chubb
Farmers Insurance
Johnson and Johnson
Accenture
Moodys
US Department of Justice
Fish and Richardson
Cerilliant

Generated: April 21, 2018

DrugPatentWatch Database Preview

Claims for Patent: 5,698,558

« Back to Dashboard

Summary for Patent: 5,698,558
Title: Methods for treating allergic disorders using optically pure (-) cetirizine
Abstract:Methods are disclosed utilizing optically pure (-) cetirizine for the treatment of seasonal and perennial allergic rhinitis in humans while avoiding the concomitant liability of adverse effects associated with the racemic mixture of cetirizine. The optically pure (-) isomer is also useful for the treatment of allergic asthma.
Inventor(s): Gray; Nancy M. (Marlboro, MA)
Assignee: Sepracor, Inc. (Marlborough, MA)
Application Number:08/789,502
Patent Claims: 1. A method of treating the symptoms of seasonal and perennial allergic rhinitis in a human which comprises administering to a human in need of such symptomatic relief therapy an amount of (-) cetirizine, or a pharmaceutically acceptable salt thereof, substantially free of its (+) stereoisomer, said amount being sufficient to alleviate or palliate said allergic rhinitis.

2. A method of treating the symptoms of seasonal and perennial allergic rhinitis in a human, while avoiding the concomitant liability of sedation associated with racemic cetirizine, which comprises administering to a human in need of such symptomatic relief therapy an amount of (-) cetirizine, or a pharmaceutically acceptable salt thereof, substantially free of its (+) stereoisomer, said amount being sufficient to alleviate or palliate said allergic rhinitis but insufficient to cause said sedation.

3. The method of claim 2 wherein (-) cetirizine is administered by intravenous infusion or orally as a tablet or a capsule.

4. The method of claim 3 wherein the amount of (-) cetirizine or a pharmaceutically acceptable salt thereof administered is from about 1 mg to about 25 mg per day.

5. The method of claim 4 wherein the amount administered is from about 2 mg to about 20 mg per day.

6. The method of claim 5 wherein the amount administered is from about 5 mg to about 10 mg per day.

7. The method of claim 2 wherein the amount of (-) cetirizine or a pharmaceutically acceptable salt thereof is greater than approximately 90% by weight of the total weight of cetirizine.

8. The method of claim 2 wherein the amount of said (-) cetirizine or a pharmaceutically acceptable salt thereof, substantially free of its (+) stereoisomer, is administered together with a pharmaceutically acceptable carrier.

9. The method according to claim 2, wherein (-) cetirizine is administered as a hydrochloride salt.

10. A method of treating allergic asthma in a human which comprises administering to a human in need of such therapy an amount of (-) cetirizine, or a pharmaceutically acceptable salt thereof, substantially free of its (+) stereoisomer, said amount being sufficient to alleviate symptoms of allergic asthma.

11. A method of treating allergic asthma in a human, while avoiding the concomitant liability of sedation associated with racemic cetirizine, which comprises administering to a human in need of such therapy an amount of (-) cetirizine, or a pharmaceutically acceptable salt thereof, substantially free of its (+) stereoisomer, said amount being sufficient to alleviate symptoms of allergic asthma but insufficient to cause said sedation.

12. The method of claim 11 wherein (-) cetirizine is administered by intravenous infusion or orally as a tablet or a capsule.

13. The method of claim 12 wherein the amount of (-) cetirizine or a pharmaceutically acceptable salt thereof administered is from about 1 mg to about 25 mg per day.

14. The method of claim 13 wherein the amount administered is from about 2 mg to about 20 mg per day.

15. The method of claim 14 wherein the amount administered is from about 5 mg to about 10 mg per day.

16. The method of claim 11 wherein the amount of (-) cetirizine or a pharmaceutically acceptable salt thereof is greater than approximately 90% by weight of the total weight of cetirizine.

17. The method of claim 11 wherein the amount of said (-) cetirizine or a pharmaceutically acceptable salt thereof, substantially free of its (+) stereoisomer, is administered together with a pharmaceutically acceptable carrier.

18. The method according to claim 11, wherein (-) cetirizine is administered as a hydrochloride salt.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Merck
Express Scripts
Chinese Patent Office
Cantor Fitzgerald
US Department of Justice
Moodys
Harvard Business School
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.